Scientists sceptical about Russia's COVID-19 vaccine, cite lack of evidence for efficacy
New Delhi: Responding with scepticism to Russia's approval of a COVID-19 vaccine, several scientists around the world, including in India, suggest it hasn't been tested properly given the time constraint and there may not be enough evidence to prove its efficacy.
Announcing the breakthrough on Tuesday, Russian President Vladimir Putin vouched for the safety and efficacy of the vaccine, named Sputnik V, and said one of his daughters has already received a shot.
While the country hopes to start mass-producing the vaccine by October and plans to offer the first doses to essential workers, many in the science community seem unimpressed.
The announcement should be taken with a pinch of salt, said Indian immunologist Vineeta Bal.
Unless some data are out in the open for people to see, including clinical trial phases and numbers, it is hard to believe that vaccine efficacy studies are successfully conducted between June 2020 and August 2020, Bal, an immunologist from the Indian Institute of Science, Education and Research in Pune, told PTI.
Are they talking about controlled human challenge studies? If yes, that evidence is also useful to examine protective efficacy, she noted.
Florian Krammer, a professor at the US-based Mount Sinai's Icahn School of Medicine, questioned the safety of the vaccine.
"Not sure what Russia is up to, but I certainly would not take a vaccine that hasn't been tested in phase 3. Nobody knows if it's safe or if it works. They are putting HCWs (health care workers) and their population at risk," Krammer said on Twitter.
Indian immunologist Satyajit Rath agreed with Krammer.
Russian authorities seem to be depending on the generation of 'neutralising' antibodies in Phase 2 clinical trials for deciding that the vaccine candidate works, he said. A neutralising antibody defends a cell from an infectious particle by neutralising any effect it has biologically.
While this is useful initial information, although even this is not really available in the public domain, it is not evidence of protective efficacy. So effectively they are bringing vaccine candidates into use without actual evidence of efficacy, the immunologist from New Delhi's National Institute of Immunology told PTI.
Describing the vaccine announcement as worrisome, Rath said it may not provide protection and may interfere with subsequent vaccine responses while causing problems for the recipients.
Vaccine testing typically begins with lab and animal model studies before going on to different stages of human trials.
The human testing phase comprises many phases.
Phase 1 trials are small-scale, usually involving a few participants, to assess whether the vaccine is safe for humans.
Phase 2 trials often involve several hundred subjects, and mainly evaluate the efficacy of the vaccine against the disease.
The final, Phase 3, involves thousands of people to further assess the efficacy of the vaccine over a defined period of time, and can last several months.
According to virologist Upasana Ray, the World Health Organisation (WHO) has asked vaccine developers to follow set guidelines.
Efficacy is checked in Phase 2 but in a few hundred people or, in other words, in a small group. In Phase 3, this efficacy, safety etc, is checked in a larger group and monitored for infection possibilities. So, yes, finishing Phase 2 is possible but not Phase 3, Ray, a senior scientist at Kolkata's CSIR-Indian Institute of Chemical Biology (CSIR-IICB), noted.
Even after the vaccine is ready, there are a lot of challenges, including whether the vaccine is effective in all populations, and if it can be used for different strains of the novel coronavirus, which might start mutating as time passes, added E. Sreekumar, chief scientific officer at Thiruvananthapuram's Rajiv Gandhi Centre for Biotechnology (RGCB).
Experts believe Phase 3 trials are where many promising vaccine candidates falter.
A 2016 study, published in the journal JAMA Internal Medicine, that analysed 640 Phase 3 drug trials in the US found that 344, or over 50 per cent, failed.
Ray said Russian authorities might have Phase 1 and 2 results, but completing Phase 3 completion so fast will be hard to believe unless the data is publicly available.
They started their trials in June. August is yet not even halfway through. How did they finish Phase 3? Maybe they just checked the efficacy i.e. Phase 2 and now starting Phase 3 simultaneously with the release of the vaccine, she said.
If that is the case, Ray said, people must be informed so that those who volunteer to get vaccinated know the facts.
From Phase 1 to 3, the number of volunteers varies from tens to hundreds to thousands, hence, clearly Phase 3 remains a question mark for Russia's vaccine, said Ray.
According to the WHO, at least six other vaccine candidates -- made by Sinovac, Sinopharm, Pfizer and BioNTech, the University of Oxford with AstraZeneca, and Moderna -- have reached Phase 3 trials globally.
At least seven Indian pharma companies are working to develop a vaccine against coronavirus as they join global efforts to find a preventive to check the spread of the deadly virus.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Petrol pump worker killed as SUV hits motorcycle head-on in Gurugram
Gurugram (PTI): A petrol pump worker died after an SUV rammed into his motorcycle in the Sushant Lok area here, police said on Thursday.
The accused driver fled the scene, leaving the vehicle after the accident. An FIR has been registered at the Sushant Lok police station, they said.
According to police, the accident occurred on Wednesday afternoon when Mukesh was travelling from Sector 44 to Sushant Lok on Vyapar Kendra Road for some work.
Near Vyapar Kendra, a white Thar coming from the wrong side at high speed hit his motorcycle head-on, leaving him critically injured, they said.
The driver fled the scene, leaving the vehicle behind, police added.
Eyewitnesses claimed the vehicle had no number plates either at the front or rear.
Locals took Mukesh to a private hospital, where he died during treatment, police said. He was a resident of Rohta Patti in Palwal and worked at a petrol pump in Sector 44.
An FIR was registered against the unidentified driver, based on a complaint lodged by his brother Ashok. The body was handed over to the family after a post-mortem on Thursday, police said.
“The Thar vehicle has been seized from the spot. CCTV footage from the area is being examined, and the driver will be arrested soon,” a Gurugram police spokesperson said.
